D. E. Shaw & Co., Inc.
- SEC CIK
- 0001009207
- Latest filing
- Aug 14, 2026
LCTX holding history
Lineage Cell Therapeutics, Inc. in every 13F filed by D. E. Shaw & Co., Inc., including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
LCTX overviewAll 13F holders of LCTXFull Q2 2026 holdings
- Shares (Q4 2024)
- 0
- Sold out in Q4 2024
- Value
- $0
- % of portfolio
- 0.0%
- Quarters held
- 10
- Since Q2 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q4 2024 | 0 | $0 | 0.0% | −25,584−100.0% | Sold out | Holders |
| Q3 2024 | 25,584 | $23.2K | <0.1% | −120,607−82.5% | Reduced | Holders |
| Q2 2024 | 146,191 | $145.8K | <0.1% | −40,436−21.7% | Reduced | Holders |
| Q1 2024 | 186,627 | $276.2K | <0.1% | +186,627 | New | Holders |
| Q4 2023 | 0 | $0 | 0.0% | −51,220−100.0% | Sold out | Holders |
| Q3 2023 | 51,220 | $60.4K | <0.1% | −71,461−58.2% | Reduced | Holders |
| Q2 2023 | 122,681 | $173.0K | <0.1% | +122,681 | New | Holders |
| Q3 2022 | 0 | $0 | 0.0% | −10,886−100.0% | Sold out | Holders |
| Q2 2022 | 10,886 | $17.0K | <0.1% | −44,585−80.4% | Reduced | Holders |
| Q1 2022 | 55,471 | $85.0K | <0.1% | −199,346−78.2% | Reduced | Holders |
| Q4 2021 | 254,817 | $624.0K | <0.1% | +67,331+35.9% | Added | Holders |
| Q3 2021 | 187,486 | $472.0K | <0.1% | +162,267+643.4% | Added | Holders |
| Q2 2021 | 25,219 | $72.0K | <0.1% | +25,219 | New | Holders |